Department of Biostatistics, University of Washington, Seattle, Washington 98112, USA.
J Urol. 2011 Aug;186(2):378-86. doi: 10.1016/j.juro.2011.03.110. Epub 2011 Jun 17.
We assessed risk factors for end stage renal disease in patients with Wilms tumor without known WT1 related syndromes. We hypothesized that patients with characteristics suggestive of a WT1 etiology (early onset, stromal predominant histology, intralobar nephrogenic rests) would have a higher risk of end stage renal disease due to chronic renal failure. We predicted a high risk of end stage renal disease due to progressive bilateral Wilms tumor in patients with metachronous bilateral disease.
End stage renal disease was ascertained in 100 of 7,950 nonsyndromic patients enrolled in a National Wilms Tumor Study during 1969 to 2002. Risk factors were evaluated with cumulative incidence curves and proportional hazard regressions.
The cumulative incidence of end stage renal disease due to chronic renal failure 20 years after Wilms tumor diagnosis was 0.7%. For end stage renal disease due to progressive bilateral Wilms tumor the incidence was 4.0% at 3 years after diagnosis in patients with synchronous bilateral Wilms tumor and 19.3% in those with metachronous bilateral Wilms tumor. For end stage renal disease due to chronic renal failure stromal predominant histology had a HR of 6.4 relative to mixed (95% CI 3.4, 11.9; p<0.001), intralobar rests had a HR of 5.9 relative to no rests (95% CI 2.0, 17.3; p=0.001), and Wilms tumor diagnosis at less than 24 months had a HR of 1.7 relative to 24 to 48 months and 2.8 relative to greater than 48 months (p=0.003 for trend).
Metachronous bilateral Wilms tumor is associated with high rates of end stage renal disease due to surgery for progressive Wilms tumor. Characteristics associated with a WT1 etiology markedly increased the risk of end stage renal disease due to chronic renal failure despite the low risk in non-WT1 syndromic cases overall.
我们评估了无 WT1 相关综合征的 Wilms 瘤患者发生终末期肾病的危险因素。我们假设具有 WT1 病因学特征(发病早、间质为主的组织学、叶内肾生殖细胞残余)的患者,由于慢性肾衰竭,终末期肾病的风险更高。我们预测,对于具有双侧 Wilms 肿瘤的患者,由于进行性双侧 Wilms 肿瘤,终末期肾病的风险较高。
1969 年至 2002 年,在全国 Wilms 肿瘤研究中纳入的 7950 例非综合征患者中,有 100 例确定为终末期肾病。采用累积发病率曲线和比例风险回归评估危险因素。
Wilms 肿瘤诊断后 20 年,慢性肾衰竭导致终末期肾病的累积发生率为 0.7%。对于双侧 Wilms 肿瘤进行性进展导致的终末期肾病,在同步双侧 Wilms 肿瘤患者中,诊断后 3 年的发生率为 4.0%,而在具有异时性双侧 Wilms 肿瘤的患者中,发生率为 19.3%。对于慢性肾衰竭导致的终末期肾病,间质为主的组织学相对于混合组织学(95%CI 3.4,11.9;p<0.001),叶内肾生殖细胞残余相对于无残余(95%CI 2.0,17.3;p=0.001),Wilms 肿瘤诊断小于 24 个月相对于 24-48 个月和大于 48 个月的 HR 分别为 1.7(p=0.003)和 2.8(p=0.003)。
异时性双侧 Wilms 肿瘤与进行性 Wilms 肿瘤手术相关的终末期肾病发生率较高。与 WT1 病因相关的特征显著增加了慢性肾衰竭导致终末期肾病的风险,尽管总体上非 WT1 综合征病例的风险较低。